Ausper Biopharma Co., Ltd.
Clinical trials sponsored by Ausper Biopharma Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New shot aims to free hepatitis b patients from daily pills Results expected Dec 2026 (estimated)
- New shot aims to cure hepatitis b without daily pills Results expected Dec 2026 (estimated)
- New injection aims to suppress hepatitis b virus Results expected Jun 2027 (estimated)
- New combo aims to cure hepatitis b without lifelong pills Results expected Jul 2027 (estimated)
- New shot aims to silence hepatitis b virus Results expected Jul 2027 (estimated)
-
New shot aims to cure chronic hepatitis b – early trial underway
Disease control CompletedThis study tests a new drug called AHB-137 in 86 adults with chronic hepatitis B who are already on standard antiviral pills. The goal is to see if AHB-137 can clear the hepatitis B surface antigen from the blood, which would mean the virus is under control and patients might be …
Phase 2 • Sponsor: Ausper Biopharma Co., Ltd. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New injection aims to tame chronic hepatitis b
Disease control CompletedThis study tests an experimental drug called AHB-137 in healthy volunteers and people with chronic hepatitis B who are already on antiviral medication. The goal is to check if the drug is safe and shows early signs of controlling the virus. About 129 participants will receive eit…
Phase 1/2 • Sponsor: Ausper Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC